Phase II/III

Type: Keyphrase
Name: Phase II/III
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

AstraZeneca and Eli Lilly enter agreement

AgreementPublished on September 17th, 2014 | by The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease.The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients ... [Published Nordic Life Science - Sep 22 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 3 reports

Lilly Joins AstraZeneca to Co-Develop BACE Inhibitor for Alzheimer's

AstraZeneca will jointly develop and commercialize its high-risk, Phase II/III-bound Alzheimer’s disease drug candidate AZD3293 with Eli Lilly , in a deal that could net AZ up to $500 million in development and regulatory milestone payments.AZD3293 is ... [Published Genetic Engineering News - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

High Hep C Cure Rates for '3D' Combo in People Coinfected With HIV

AbbVie’s “3D” regimen cured high rates of genotype 1 of hepatitis C virus (HCV) among people coinfected with HIV. Reporting their findings at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, investigators conducted the first ... [Published POZ.com - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Quintiles Launches New Customer Solution to Meet the Unique Needs of Emerging Biopharmaceutical Companies

Deliver more with lessSuccess can be transformational for emerging companies. But the path is paved with challenges, including constrained budgets, limited internal resources and the need to demonstrate progress to investors. We understand that you must ... [Published Al Shams Info - Sep 12 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Researchers at National Hospital Organization Release New Data on Clinical Trials and Studies [Randomized Phase II/III Trial of Post-operative...

Researchers at National Hospital Organization Release New Data on Clinical Trials and Studies [Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with ...]By a News ... [Published Pharmacy Choice - Sep 09 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 2 reports

C-Suite Conversation: Can-Fite BioPharma CEO Pnina Fishman

By Robert Lakin :My interview with Can-Fite (NYSEMKT: CANF ) Chief Executive Officer Dr. Pnina Fishman is the latest in my series of interviews with under-covered Israeli companies that trade on U.S. exchanges.Related Biotechnology, Pharmaceutical and ... [Published BioPortfolio - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Scottish independence fears boost shekel against sterling

As the latest opinion polls give the "Yes" to independence vote a slender lead, sterling is weakening worldwide.Sterling has taken a plunge against all world currencies as the latest opinion polls see Scotland voting "yes" to independence in the September ... [Published Globes - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Torii initiates Phase II/III Japanese cedar tree pollen allergy trial

ALK-Abello A/S, a research-driven pharmaceutical company, has announced that its partner, Torii Pharmaceuticals has initiated a Phase II/III clinical trial in Japan for new sublingual immunotherapy tablet, or SLIT-tablet, for the treatment of Japanese ... [Published Individual.com - Sep 08 2014]
Entities: Phase II/III, Cedar, Pollen
First reported Sep 04 2014 - Updated Sep 05 2014 - 1 reports

Can-Fite BioPharma Reports First Six Months 2014 Results [Global Data Point]

? CF101 - Completes patient enrollment in Phase II/III trial for the treatment of psoriasisCan-Fite has completed enrollment of over 300 patients at 17 clinical centers in the U.S., Europe, and Israel in its Phase II/III trial for the treatment of psoriasis. ... [Published Pharmacy Choice - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Sector Update: Health Care Stocks Finish Lower; HealthSouth Sinks on Plans for $175 Mln Senior Notes Offering

PFE -0.19%ABT +0.26%MRK -0.74%AMGN -0.40%Healthcare stocks were ending lower Thursday with the NYSE Healthcare Sector Index slipping about 0.6% and shares of healthcare companies in the S&P 500 also falling about 0.6% as a group.In company news, HealthSouth ... [Published Nasdaq - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 2 reports

Kamada plunges on lung treatment results

The company confirmed that its AAT product for hereditary emphysema did not meet its Phase II/III trial endpoints.Kamada Ltd. (Nasdaq: KMDA); TASE: KMDA) today confirmed the results of its initial trial published three and a half months ago. At that time, ... [Published Globes - Sep 04 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 3 reports

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

Japanese drugmaker Torii Pharmaceutical has begun a Phase II/III development program with Denmark-based allergy specialist ALK Abello (ALKB: DC) for a new allergy immunotherapy tablet to treat Japanese cedar tree pollen allergy.Torii, a strategic partner ... [Published Pharma Letter - Sep 02 2014]
Entities: Cedar, Pollen, Immunotherapy

Quotes

"The results of this study are an important step forward for the treatment of ALL patients that are at risk to receive L-asparaginase, which remains an important unmet medical need. The virtual absence of allergic reactions, also in patients with prior allergies to L-asparaginase, is very encouraging." comments Professor Yves Betrand, hemato-oncologist at IHOP (Institute for Pediatric Hematology and Oncology) in Lyon (France) and principal investigator...
"The treatment of post-surgery liver function is an indication that would complement our current portfolio of indications in clinical trials. CF102 may offer important healing benefits for the liver not only to cancer patients, but also for patients who have other diseases or injuries of the liver" stated Can-Fite CEO Pnina Fishman
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "It is a well-deserved validation of Ablatherm HIFU to have it highlighted in such a prestigious international conference that is attended by urologists from around the world. Interest in HIFU in the treatment of prostate cancer is growing worldwide and EDAP, with its Ablatherm®-HIFU and Focal One® devices for the treatment of localized prostate cancer, is well positioned to address this highly prevalent global medical need."
...expertise in treating Alzheimer's disease," said Mene Pangalos, executive vice president, Innovative Medicines & Early Development at AstraZeneca. "We believe that, by combining the scientific expertise from our two organizations and by sharing the risks and cost of late-stage development, we will be able to accelerate the advancement of AZD3293 and progress a promising new approach to support the treatment of Alzheimer's patients around the world."

More Content

All (78) | News (67) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Erytech reports positive Phase III results from... [Published Pharma Letter - 10 hours ago]
7-Year-Old Jack Fowler Needs Care2 Members to H... [Published Care2 - 10 hours ago]
ERYTECH Reports Positive Top-Line Phase III Res... [Published BusinessWeek - Sep 30 2014]
U.S. Patent and Trademark Office Issues Can-Fit... [Published Securities Technology Monitor - Sep 30 2014]
Soligenix: A Low Risk, High Return Biotech Stock [Published Yahoo! Finance - Sep 23 2014]
Stock Analysts’ Ratings Reiterations for Septem... [Published Mideast Time - Sep 23 2014]
AstraZeneca and Eli Lilly enter agreement [Published Nordic Life Science - Sep 22 2014]
EDAP's Ablatherm(R)-HIFU Technology Highlighted... [Published Market Pulse Navigator - Sep 22 2014]
The Pathogenesis, Diagnosis and Treatment of Lu... [Published General Medicine eJournal - Sep 19 2014]
Lilly, AZ Enter Alzheimer’s Alliance [Published Contract Pharma - Sep 16 2014]
Lilly Joins AstraZeneca to Co-Develop BACE Inhi... [Published Genetic Engineering News - Sep 16 2014]
Lilly takes the lead on AstraZeneca's Alzheimer... [Published FierceBiotech - Sep 16 2014]
AstraZeneca teams up with rival Lilly for Alzhe... [Published Pharmafocus - Sep 16 2014]
Lilly to pay up to $500 million for AstraZeneca... [Published Pharma Letter - Sep 16 2014]
AZ could bank $500 million in Lilly Alzheimer's... [Published Pharma Times - Sep 16 2014]
AstraZeneca, Eli Lilly partner to develop BACE ... [Published FirstWord Pharma - Sep 16 2014]
UPDATE 1-AstraZeneca gets up to $500 mln from L... [Published CNBC - Sep 16 2014]
AstraZeneca, Lilly To Jointly Develop AZD3293 F... [Published RTTNews.com - Sep 16 2014]
AstraZeneca, Lilly Reach Deal On BACE Inhibitor... [Published RTTNews.com - Sep 16 2014]
AstraZeneca and Lilly announce alliance to deve... [Published AstraZeneca - Sep 16 2014]
High Hep C Cure Rates for '3D' Combo in People ... [Published POZ.com - Sep 15 2014]
ReWalk Robotics raises $36m in Nasdaq IPO [Published Globes - Sep 14 2014]
Update: Cellceutix's Antibiotic Brilacidin Shou... [Published Seeking Alpha - Sep 14 2014]
Gastric Cancer: Perioperative Chemotherapy Impr... [Published Oncology Times - Sep 13 2014]
Quintiles Launches New Customer Solution to Mee... [Published Al Shams Info - Sep 12 2014]
Quintiles Launches New Customer Solution to Mee... [Published Investor's Business Daily - Sep 12 2014]
Futura Medical PLC Interim Results Replacement [Published ADVFN UK - Sep 11 2014]
Can-Fite Issued Japanese Patent for CF102 in th... [Published CWEB News - Sep 11 2014]
Futura Medical : Interim Results for the six mo... [Published 4 Traders - Sep 11 2014]
Melanoma: Concurrent Immunotherapy with Ipilimu... [Published Oncology Times - Sep 11 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cold Genesys snags $13.57 mln Series A [Published PE Hub Blog - Jul 31 2014]
Cold Genesys has raised $13.57 million in Series A financing from Ally Bridge Group . Based in Newport Beach, Calif., CGI is a clinical-stage biopharmaceutical firm developing oncolytic immunotherapies for cancer. PRESS RELEASE NEWPORT BEACH, Calif., ...
Cold Genesys Raises $13.57 Million in a Series ... [Published Business Wire Health News - Jul 30 2014]
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured financing of $13.57 million from Ally Bridge Group. ...
AgeneBio Appoints Industry Leaders Patrick LePo... [Published Marketwire - Breaking News Releases - Jul 25 2014]
Appointments Complete Leadership Team to Advance Development Programs Including a Product Candidate in Phase II/III to Slow the Progression of Alzheimer's Disease ...
Can-Fite Completes Patient Enrollment in its Ph... [Published PR Newswire: Health - Jun 17 2014]
PETACH TIKVA, Israel, June 17, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has ...
Kamada Announces Preliminary Results from Phase... [Published Business Wire Health News - May 16 2014]
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada ...
1 2

Press Releases

sort by: Date | Relevance
AstraZeneca and Lilly announce alliance to deve... [Published AstraZeneca - Sep 16 2014]
ALK’s partner for Japan announces trial results... [Published GlobeNewswire: Acquisitions News - Jun 16 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.